Effect of Obese and Lean Zucker Rat Sera on Human and Rat Prostate Cancer Cells: Implications in Obesity-Related Prostate Tumor Biology

Urology

Volumn 69, Issue 1, 2007, Pages 191-195

  Lamarre, Neil S ^a   Ruggieri Sr , Michael R ^a   Braverman, Alan S ^a   Gerstein, Matthew I ^a   Mydlo, Jack H ^a  

^a TEMPLE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETONITRILE DERIVATIVE; CHARCOAL; FIBROBLAST GROWTH FACTOR 2; VASCULOTROPIN;

ANIMAL CELL; ARTICLE; BLOOD LEVEL; CANCER CELL; CANCER CELL CULTURE; CELL PROLIFERATION; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; HUMAN CELL; MALE; MITOGENICITY; NONHUMAN; OBESITY; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN DETERMINATION; RAT; TEST STRIP; ZUCKER RAT;

ANIMALS; CELL PROLIFERATION; FEMALE; FIBROBLAST GROWTH FACTOR 2; HUMANS; MALE; OBESITY; PROSTATE; PROSTATIC NEOPLASMS; RATS; RATS, ZUCKER; SERUM; TUMOR CELLS, CULTURED; VASCULAR ENDOTHELIAL GROWTH FACTORS;

EID: 33846488961     PISSN: 00904295     EISSN: 15279995     Source Type: Journal    
DOI: 10.1016/j.urology.2006.09.063     Document Type: Article

References (28)

1. American Cancer Society: Cancer facts and figures 2004. Available at: www.cancer.org/downloads/STT/CAFF_finalPWSecured.pdf. Accessed November 22, 2004.
2. Kolonel L.N., Nomura A.M., and Cooney R.V. Dietary fat and prostate cancer: current status. J Natl Cancer Inst 91 (1999) 414-419
3. Yatani R., Chigusa I., Akazaki K., et al. Geographic pathology of latent prostatic carcinoma. Int J Cancer 29 (1982) 6611-616
4. Wynder E.L., Fujita Y., Harris R.E., et al. Comparative epidemiology of cancer between the United States and Japan: a second look. Cancer 67 (1991) 746-750
5. Hsing A.W., Chang L., Nomura A.M., et al. A glimpse into the future. Epidem Rev 23 (2001)
6. Whittemore A.S., Kolonel L.N., Wu A.H., et al. Prostate cancer in relation to diet, physical activity, and body size in blacks, whites, and Asians in the United States and Canada. J Natl Cancer Inst 87 (1995) 652-663
7. Mydlo J.H., Kanter J.L., Kral J.G., et al. The role of obesity and diet in urological carcinogenesis. BJU Int 84 (1999) 225-234
8. Mydlo J.H., Gerstein M.I., Harris C.F., et al. Immune function, mitogenicity, and angiogenic growth factor concentrations in lean and obese rodent sera: implications in obesity-related prostate tumor biology. Prostate Cancer Prostatic Dis 6 (2003) 286-289
9. Chen J., De S., Brainard J., et al. Metastatic properties of prostate cancer cells are controlled by VEGF. Cell Comm Adhes 11 (2004) 1-11
10. Strohmeyer D., Strauss F., Rossing C., et al. Expression of bFGF, VEGF, and c-met and their correlation of microvascular density in the progression of prostate carcinoma. Anti Cancer Res 24 (2004) 1794-1804
11. Trojan L., Thomas D., Knoll T., et al. Expression of pro-angiogenic growth factors VEGF, EGF, and bFGF and their topographical relation to neovascularity in prostate cancer. Urol Res 32 (2004) 97-103
12. Li H., Kontoff P.W., Ma J., et al. Prediagnostic plasma vascular endothelial cell growth factor levels and risk of prostate cancer. Cancer Epidemiol Biomarkers 14 (2005) 1557-1561
13. Takaya K., Ogawa Y., Isse N., et al. Molecular cloning of rat leptin receptor isoform complementary DNAs-identification of a missense mutation in Zucker fatty (fa/fa) rats. Biochem Biophys Res Comm 225 (1996) 75-80
14. Kurtz T.W., Morris R.C., and Pershadsingh H.A. The Zucker fatty rat as a genetic model of obesity and hypertension. Hypertension 13 (1989) 896-891
15. Isaacs J.T., Isaacs W.B., Feitz W.F., et al. Establishment and characterization of seven Dunning rat prostatic cancer cell lines and their use in developing methods for predicting metastatic abilities of prostatic cancers. Prostate 9 (1986) 261-268
16. Giagulli V.A., Kaufman J.M., and Vermeulen A. Pathogenesis of the decreased androgen levels in obese men. J Clin Endocrinol Metab 79 (1994) 997-1002
17. Kelloff G.J., Lubet R.A., Lieberman R., et al. Aromatase inhibitors as potential cancer chemopreventives. Can Epidemiol Biomarkers Prev 7 (1998) 65-69
18. Ahima R.S., and Flier J.S. Leptin. Ann Rev Physiol 62 (2000) 413-416
19. Sierra-Honigmann M.R., Nath A.K., Murakami C., et al. Biological action of leptin as an angiogenic factor. Science 281 (1998) 1683-1689
20. Saglam K., Aydur E., Yilmaz M., et al. Leptin influences cellular differentiation and progression in prostate cancer. J Urol 169 (2003) 1308-1311
21. Onuma M., Bub J.D., Rummel T.L., et al. Prostate cancer cell-adipocyte interaction: leptin mediates androgen-independent prostate cancer cell proliferation through c-Jun NH2-terminal kinase. J Biol Chem 278 (2003) 42660-42669
22. Horoszewicz J.S., Leong S.S., Kawinski E., et al. LNCaP model of human prostatic carcinoma. Cancer Res 43 (1983) 1809-1812
23. Patel B.J., Pantuck A.J., Zisman A., et al. CLI-1: an androgen independent metastatic tumor model for prostate cancer. J Urol 164 (2000) 1420-1425
24. Strom S.S., Wang X., Pettaway C.A., et al. Obesity, weight gain and risk of biochemical failure among prostate cancer patients following prostatectomy. Clin Cancer Res 11 19 Pt 1 (2005) 6889-6894
25. Bradbury B.D., Wilk J.B., and Kaye J.A. Obesity and the risk of prostate cancer. Cancer Causes Control 16 (2005) 637-641
26. Bassett W.W., Cooperberg M.R., Sadetsky N., et al. Impact of obesity on prostate cancer recurrence after radical prostatectomy. Urology 66 (2005) 1060-1065
27. Mallah K.N., DiBlasio C.J., Rhee A.C., et al. Body mass index is weakly associated with, and not a helpful predictor of, disease progression in men with clinically localized prostate carcinoma treated with radical prostatectomy. Cancer 103 (2005) 2030-2034
28. Freeland S.J., Giovannucci E., and Platz E.A. Are findings from studies of obesity and prostate cancer really in conflict?. Cancer Causes Control 17 (2006) 5-9